Search results
Results from the WOW.Com Content Network
Tafamidis, sold under the brand names Vyndaqel and Vyndamax, [5] is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis. It can be used to treat both hereditary forms, familial amyloid cardiomyopathy and familial amyloid polyneuropathy , as well as wild-type transthyretin amyloidosis , which ...
Researchers examined all studies between 1984 and 2024 which reported on survival or nursing home admission for people with dementia. A total of 235 studies reported on survival among more than 5. ...
New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study estimates. ... Even a rough estimate of how long a person with dementia ...
The hallmark symptom of LATE is a progressive memory loss that predominantly affects short-term and episodic memory. [1] This impairment is often severe enough to interfere with daily functioning and usually remains the chief neurologic deficit, unlike other types of dementia in which non-memory cognitive domains and behavioral changes might be noted earlier or more prominently. [1]
ICD-10 is the 10th revision of the International Classification of Diseases (ICD), a medical classification list by the World Health Organization (WHO). It contains codes for diseases, signs and symptoms, abnormal findings, complaints, social circumstances, and external causes of injury or diseases. [1]
Frontotemporal dementia (FTD) is an early onset disorder that mostly occurs between the ages of 45 and 65, [13] but can begin earlier, and in 20–25% of cases onset is later. [11] [14] Men and women appear to be equally affected. [15] It is the most common early presenting dementia. [16]
Also known as tafamidis, Vyndaqel and Vyndamax treat transthyretin amyloid cardiomyopathy, a rare condition that causes the heart to stiffen, impedes blood flow and can lead to progressive heart ...
Binswanger's disease is a type of subcortical vascular dementia caused by white matter atrophy to the brain. However, white matter atrophy alone is not sufficient for this disease; evidence of subcortical dementia is also necessary.